A drug maker in India, Zydus Cadila, has become the first pharma company worldwide to secure a regulatory agency greenlight for a non-alcoholic steatohepatitis (NASH) therapy (Saroglitazar) as the Drug Controller General of India (DCGI) approved the drug. TrialSite...
NAFLD
Category
University of Manitoba Commences Study to Understand why NAFLD Rates so High in this Part of Canada
The University of Manitoba Department of Internal Medicine’s Section of Hepatology is undertaking a five-year study to identify why Nonalcoholic fatty liver disease (NAFLD) is the most prevalent disease in Canada, with the Canadian Liver Foundation estimates 25% of...
Breakthrough Liver Disease Detection Technology Developed by HISKY MED & Tsinghua University Coming to America
Wuxi Hisky Medical Technologies Co Ltd, a Chinese medical device venture, has launched an innovative, non-invasive liver disease detection product. Called iLivTouch, the company uses multichannel imaging-guided transient elastography, a breakthrough in related medical...
India’s First NAFLD Center of Excellence for Clinical Trials Originates from ILBS & HistoIndex
HistoIndex and the Institute of Liver & Biliary Sciences (ILBS) in New Delhi, India have jointly launched a Centre of Excellence (CoE) to aid diagnostics and clinical trials focusing on NASH. What is the CoE? The CoE is HistoIndex’s first Genesis Imaging Service...
UPMC Breakthrough: Miniature Livers Grown for NAFLD Drug Tests Reflect Real-World Outcomes
UPMC McGowan Institute for Regenerative Medicine spearheads the growing of genetically modified miniature human livers to emulate human liver disease progression and support ongoing therapeutics testing. Reporting in the UPMC news, the results were published in a...
Research Shows Weight Loss Mediates CV Damage of Fatty Liver in Diabetes
Dr. Samuel Klein declares that nonalcoholic fatty liver is an “unrecognized epidemic” among people with type 2 diabetes. Metabolic complications arise with the development of obesity—including NAFLD and its more severe state, nonalcoholic steatohepatitis (NASH),...
High Point Clinical Trials Center Participates in NASH Pass Initiative Focusing on Accelerating Clinical Trial Recruitment
High Point Clinical Trials Center, LLC (HPCTC), the largest independent clinical research site in North Carolina, reports it has partnered with ProSciento, a specialized CRO exclusively focused on metabolic diseases, to join as a NASH PASS site partner. ProSciento has...
UCSD Research Shows Low Sugar Diet Effective in Boys with Nonalcoholic Fatty Liver Disease
As reported in EurekAlert! University of California San Diego School of Medicine and Emory University School of Medicine researchers found that a diet low in free sugars (those added to foods and beverages and occurring naturally in fruit juices) resulted in...